• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: VILEX, LLC CHI; CANNULATED MET HEAD IMPLANT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

VILEX, LLC CHI; CANNULATED MET HEAD IMPLANT Back to Search Results
Device Problem Improper or Incorrect Procedure or Method (2017)
Patient Problem Metal Related Pathology (4530)
Event Date 11/19/2018
Event Type  Injury  
Event Description
Patient was implanted with vilex mpj implants on (b)(6)2018 to address chronic gout.Approximately 6 months post-op, patient begain experiencing pain and periodic swelling at the surgical site.Several years later, patient underwent a revision surgery.During this surgery, dark grey discoloration was present at the mpj joint site.Vilex implants were removed and the joint was fused with a plate.
 
Manufacturer Narrative
Patient contacted vilex on (b)(6)2023 to address the issues he had after being implanted with chi mpj implants.Patient was initially implanted with vilex mpj implants on (b)(6) 2018 to address chronic gout.Patient began experiencing pain and periodic swelling at the surgical site 6 months post-op and over the next few years.On (b)(6) 2023, patient underwent a revision surgery and dark gray discoloration was present at the mpj joint site.The vilex implants were removed and the joint was fused with a plate.Implants were not returned for evaluation.Patient provided photos of the explanted implants and the surgical site where the discoloration is visible.Based on the photos and procedure report provided by the patient, it was determined that the most likely cause of the dark gray discoloration at the joint site is the presence of titanium particulate resulting from metal-on-metal articulation of two implanted hemi devices.At the first metatarsophalangeal joint, the surgeon resected the surfaces of the proximal phalanx as well as the metatarsal head and implanted both chi and cmhi implants at those locations, respectively, which is not the intended use of the devices.The surgical technique for these devices states 'depending on the condition of the joint, the surgeon has the option to replace eiether the head of the metatarsal or the base of the phalanx, but not both.Under no circumstance should both ends of the joint be replaced.Without any condition or equivocation vilex does not recommend the replacement of both the base of the phalanx and metatarsal head of the same joint.' this is the first occurrence of this type of incident vilex has been made aware of regarding the hemi devices.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
CHI
Type of Device
CANNULATED MET HEAD IMPLANT
Manufacturer (Section D)
VILEX, LLC
111 moffitt street
mcminnville TN 37110
Manufacturer (Section G)
VILEX, LLC
111 moffitt street
mcminnville TN 37110
Manufacturer Contact
emily womack
111 moffitt street
mcminnville, TN 37110
9314747552
MDR Report Key18610998
MDR Text Key334141919
Report Number1051526-2024-00001
Device Sequence Number1
Product Code KWD
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
K102401
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Company Representative
Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date 01/18/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received01/30/2024
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received12/29/2023
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient SexMale
-
-